Compounds > adenine

adenine and cilostamide

adenine has been researched along with cilostamide in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (50.00)18.2507
2000's1 (25.00)29.6817
2010's0 (0.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
Maurice, DH; Palmer, D; Tsoi, K1
Benelli, C; Clot, JP; Desbuquois, B; Fouque, F; Geoffroy, V; Lugnier, C; Nivet, V1
Hernández, J; Juan-Fita, MJ; Vargas, ML1
Gergs, U; Laufs, U; Neumann, J; Voss, R; Werner, C1

Other Studies

4 other study(ies) available for adenine and cilostamide

ArticleYear
Synergistic inhibition of vascular smooth muscle cell migration by phosphodiesterase 3 and phosphodiesterase 4 inhibitors.
    Circulation research, 1998, May-04, Volume: 82, Issue:8

    Topics: 1-Methyl-3-isobutylxanthine; 3',5'-Cyclic-AMP Phosphodiesterases; 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; Adenine; Animals; Aorta; Becaplermin; Cell Movement; Cells, Cultured; Colforsin; Cyclic Nucleotide Phosphodiesterases, Type 3; Cyclic Nucleotide Phosphodiesterases, Type 4; Drug Synergism; Humans; Kinetics; Muscle, Smooth, Vascular; Phosphodiesterase Inhibitors; Platelet-Derived Growth Factor; Proto-Oncogene Proteins c-sis; Quinolones; Rats; Recombinant Proteins

1998
Activation of a cGMP-stimulated cAMP phosphodiesterase by protein kinase C in a liver Golgi-endosomal fraction.
    European journal of biochemistry, 1999, Volume: 259, Issue:3

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adenine; Animals; Cyclic AMP-Dependent Protein Kinases; Cyclic GMP; Endosomes; Enzyme Activation; Enzyme Inhibitors; Golgi Apparatus; Liver; Male; Naphthalenes; Phosphodiesterase Inhibitors; Protein Kinase C; Quinolones; Rats; Rats, Sprague-Dawley; Tetradecanoylphorbol Acetate; Time Factors

1999
The phosphodiesterase 3 inhibitor cilostamide enhances inotropic responses to glucagon but not to dobutamine in rat ventricular myocardium.
    European journal of pharmacology, 2005, Apr-11, Volume: 512, Issue:2-3

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adenine; Adrenergic beta-Antagonists; Animals; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 3; Dobutamine; Dose-Response Relationship, Drug; Drug Synergism; Exonucleases; Female; Glucagon; Heart Ventricles; Imidazoles; In Vitro Techniques; Male; Myocardial Contraction; Phosphodiesterase I; Phosphodiesterase Inhibitors; Purinergic P1 Receptor Antagonists; Quinolones; Rats; Rats, Sprague-Dawley; Ventricular Function; Xanthines

2005
Phosphodiesterases 2, 3 and 4 can decrease cardiac effects of H
    Naunyn-Schmiedeberg's archives of pharmacology, 2021, Volume: 394, Issue:6

    Topics: Adenine; Animals; Cyclic Nucleotide Phosphodiesterases, Type 2; Cyclic Nucleotide Phosphodiesterases, Type 3; Cyclic Nucleotide Phosphodiesterases, Type 4; Female; Heart Atria; Heart Rate; Histamine; Humans; Male; Mice; Mice, Transgenic; Phosphodiesterase Inhibitors; Quinolones; Receptors, Histamine H2; Rolipram

2021